Hoth Therapeutics (HOTH) has entered into a Master Services Agreement with Aronnax for its HT-KIT cancer therapeutic. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT being developed for the treatment of mast cell-derived cancers and anaphylaxis and previously received Orphan Drug Designation from FDA.
"This further analysis will help us with that process, finalizing the protocols in our upcoming IND-enabling study. We are pleased to further engage Aronnax and ITR Laboratories on these key studies given their reputation for IND-enabling studies," stated Robb Knie, CEO.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.